Traders Buy High Volume of OPKO Health Call Options (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) saw some unusual options trading activity on Monday. Investors purchased 9,645 call options on the stock. This is an increase of approximately 402% compared to the typical volume of 1,921 call options.

Analysts Set New Price Targets

Several brokerages recently commented on OPK. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Barrington Research reissued an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Wednesday, January 8th.

Insider Activity

In related news, CEO Phillip Md Et Al Frost bought 199,072 shares of the stock in a transaction on Friday, November 29th. The shares were purchased at an average price of $1.53 per share, with a total value of $304,580.16. Following the purchase, the chief executive officer now owns 211,911,477 shares in the company, valued at approximately $324,224,559.81. This represents a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders bought 1,521,609 shares of company stock valued at $2,313,710. 47.26% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On OPKO Health

Several large investors have recently modified their holdings of OPK. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in OPKO Health by 24.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company’s stock worth $1,107,000 after purchasing an additional 148,322 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in shares of OPKO Health by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,396 shares during the period. Two Sigma Investments LP boosted its holdings in shares of OPKO Health by 136.1% in the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after buying an additional 949,671 shares during the period. ProShare Advisors LLC boosted its holdings in shares of OPKO Health by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company’s stock worth $135,000 after buying an additional 30,182 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in shares of OPKO Health by 42.3% in the fourth quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock worth $2,106,000 after buying an additional 425,484 shares during the period. 64.63% of the stock is owned by institutional investors.

OPKO Health Price Performance

OPK stock traded up $0.05 on Monday, hitting $1.73. 863,064 shares of the company’s stock traded hands, compared to its average volume of 2,717,248. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -9.08 and a beta of 1.63. OPKO Health has a 1-year low of $0.86 and a 1-year high of $1.76. The stock has a fifty day moving average of $1.54 and a 200-day moving average of $1.54.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.